Decision Makers
Board of Directors
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Chief Executive Officer, President and Chairman of the Board |
Current |
| Chem-Bio |
President and Director |
Current |
| Stockguru.Com |
|
Current |
| Chem-Bio |
Chairman |
Current |
| Siebert & Associates Inc |
Broker |
Former |
| Stanwich Partners |
|
Former |
| Case Western Reserve University |
Jd |
Former |
| University of Connecticut |
Ba With Distinction In Economics |
Former |
Mr. Larkin oversees Chembio's financial activities and information systems. He has been Chief Financial Officer of Chembio Diagnostic Systems, Inc. since September 2003. Prior to joining Chembio Diagnostic Systems Inc., Mr. Larkin served as CFO at Visual Technology Group from May 2000 to September 2003. He led their consultancy program providing hands-on expertise in all aspects of financial service, including initial assessment of client financial reporting requirements within an Enterprise Resource Planning (Manufacturing) environment. Prior to joining VTG, he served as CFO at Protex International Corporation from May 1987 to January 2000. Mr. Larkin holds a BBA in Accounting from Dowling College and is a member of the American Institute of Certified Public Accountants.
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Executive Vice President of Commercial Operations |
Current |
| American Bio Medica Corporation |
Chief Executive Officer |
Former |
| American Bio Medica Corporation |
Interim President |
Former |
| Chembio Diagnostics, Inc. |
Senior Vice President, Commercial Operations |
Former |
| K Street Associates LLC |
Founder |
Former |
| Roche Diagnostic Systems, Inc. |
Director of Global Marketing |
Former |
| Hunterdon Drug Awareness Program, Inc |
Board Member |
Former |
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Senior Vice President, Research & Development |
Current |
| Stockguru.Com |
|
Current |
| Lund University |
B.Sc. in Clinical Chemistry and his M |
Former |
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Vice President Sales, Marketing and Business Development |
Current |
| Stockguru.Com |
|
Current |
| IMS Group |
Managing Director |
Former |
| IMS Group |
Co-Founder |
Former |
| Chembio Diagnostics, Inc. |
Marketing Executive |
Former |
| Chem-Bio |
|
Former |
| New York University |
MBA in finance and international business |
Former |
| University of Michigan |
BA with Distinction in economics |
Former |
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Vice President of Regulatory Affairs, Quality Assurance and Quality Control |
Current |
| The University of Tennessee |
PhD |
Former |
In 2005, Mr. Stutzman joined Chembio as Vice President of Marketing to lead the development and launch of rapid tests for veterinary and human TB and other veterinary products. Mr. Stutzman has spent over twenty years in marketing leadership positions within various diagnostics companies. He has held Global Director and Business Development Director positions in Marketing for diagnostic companies including bioMerieux Inc., (formerly Organon Teknika Corp.), Durham, North Carolina and TREK Diagnostic Systems, Cleveland, Ohio. Mr. Stutzman received his MBA in Marketing from Duke University Fuqua School of Business in 1988 and his Masters in Microbiology from Wagner College in 1982. Mr. Stutzman is MT (ASCP) SM certified.
| Organization |
Position |
Status |
| Chem-Bio |
Vice President, Marketing |
Current |
| Chembio Diagnostics, Inc. |
Vice President, Marketing |
Current |
| Biomerieux, Inc |
Business Development Director |
Former |
| Wagner College |
Masters In Microbiology |
Former |
| Duke University, The Fuqua School of Business |
Mba In Marketing |
Former |
Tom Ippoli to ( 4 6 ), VP of Regulatory Affairs, QA and QC. Mr. Ippolito joined Chembio in June 2005. He has over twenty years experience with in vitro diagnostics for infectious diseases, protein therapeutics, vaccine development, Process Development, Regulatory Affairs and Quality Management. Over the years, Mr. Ippolito has held Vice President level positions at Biospecific Technologies, Corp. from 2000 - 2005, Director level positions in Quality Assurance, Quality Control, Process Development and Regulatory Affairs at United Biomedical, Inc. from 1987 - 2000. Mr. Ippolito is the Course Director for "drug development process" and "FDA Regulatory Process" for the BioScience Certificate Program at the New York State University of Stony Brook, a program he has been a part of since its inception in 2003.
Mr. Ippolito joined Chembio in June 2005. He has over 20 years experience with in vitro diagnostics for infectious diseases, protein therapeutics, vaccine development, Process Development, Regulatory Affairs and Quality Management. Over the years, Mr. Ippolito has held Vice President level positions at Biospecific Technologies, Corp., Director level positions in Quality Assurance, Quality Control, Process Development and Regulatory Affairs at United Biomedical, Inc. Mr. Ippolito is also the Course Director "drug development process" and "FDA regulations", a BioScience Certificate program at New York State University of Stony Brook.
| Organization |
Position |
Status |
| Chem-Bio |
Vice President, Regulatory Affairs, Qa & Qc |
Current |
| Chembio Diagnostics, Inc. |
Vice President of Regulatory Affairs, Quality Assurance and Quality Control |
Current |
| Stockguru.Com |
|
Current |
| United Biomedical Inc. |
guest instructor |
Former |
| The State University of New York |
Certificate Program |
Former |
Dr. Gary Meller (55), Director. Dr. Meller was elected to our Board of Directors on March 15, 2005. Dr. Meller has been the president of CommSense Inc., a healthcare business development company, since 2001. CommSense Inc. works with clients in Europe, Asia, North America, and the Middle East on medical information technology, medical records, pharmaceutical product development and financing, health services operations and strategy, and new product and new market development. From 1999 until 2001 Dr. Meller was the executive vice president, North America, of NextEd Ltd., a leading internet educational services company in the Asia Pacific region. Dr. Meller also is a limited partner and a member of the Advisory Board of Crestview Capital Master LLC, which was the lead investor in our series B preferred stock private placement. Dr. Meller is a graduate of the University of New Mexico School of Medicine and has an MBA from the Harvard Business School.
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Director, Chairman of The Compensation Committee, Member of The Audit & Nominating Committees |
Current |
| Chembio Diagnostics, Inc. |
Director |
Current |
| Nexted Limited |
Executive Vice President |
Former |
| University of New Mexico School of Medicine |
|
Former |
| Organization |
Position |
Status |
| Davis Design Group |
Owner |
Current |
| Chembio Diagnostics, Inc. |
Director, Chairman of The Nominating and Audit Committees, Member of Compensation Committee |
Current |
| Chembio Diagnostics, Inc. |
Board of Directors |
Current |
| Global Access Point |
Chief Executive Officer |
Former |
| The City of Indianapolis .Com |
Controller |
Former |
Mr. Carus was elected to Chembio's Board of Directors on April 15, 2005. He is a co-founder of LARC Strategic Concepts LLC, a consulting firm dedicated to guiding emerging companies to next stage development. Prior to co-founding LARC Strategic Concepts LLC, Mr. Carus was Senior Vice President of Maritime Overseas Corporation ("MOC") and a senior executive of Overseas Ship holding Group, Inc. ("OSG") from 1981 to 1998 when he retired. MOC was managing agent for OSG, one of the world's largest ship-owners. He was a member of OSG's senior management committee and had senior responsibility in areas relating to administration, accounting, tax, finance, budgets, long-range projections, and human resources. Mr. Carus was involved in numerous acquisitions, debt and equity offerings, complex transaction structuring, and was active in the management of OSG's major investments in the cruise industry and other development stage companies. From 1964 to 1981, he was with Ernst & Young (including predecessors), the last seven years as a partner. Mr. Carus has a B.B.A. from the Baruch School of Business of the City College of New York.
| Organization |
Position |
Status |
| Emeritus Capital Partners, LLC |
General Counsel |
Current |
| Emeritus Capital Partners, LLC |
Vice Chairman |
Current |
| GIF Acceptance |
Board of Directors |
Current |
| Chembio Diagnostics, Inc. |
Board of Directors |
Current |
| George Washington Law Review |
Lead Articles Editor |
Former |
| The George Washington University Law School |
J.D. |
Former |
| Organization |
Position |
Status |
| Chembio Diagnostics, Inc. |
Director |
Current |
| HemoSense, Inc. |
CEO |
Former |
| HemoSense, Inc. |
President |
Former |
| Boehringer Mannheim |
|
Former |
| HemoSense, Inc. |
Director |
Former |
| Nebraska Wesleyan University |
Bachelor of Science degree in Biology |
Former |
| Organization |
Position |
Status |
| Business Consulting Group Unlimited, Inc |
Managing Director |
Current |
| Arpad Energy, Inc. |
General Counsel |
Current |
| Chembio Diagnostics, Inc. |
Director |
Current |
| Business Consulting Group Unlimited, Inc |
Founder |
Former |
Executive News